Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Teijin Pharma Of Japan To Apply For Clinical Trial Approval Of Gout Drug In China

This article was originally published in PharmAsia News

Executive Summary

Teijin Pharma will apply for clinical trial approval for Uloric (febuxostat, TMX-67) to treat gout and hyperuricemia in China. The Tokyo-based drug and medical maker plans to conduct the trials in China using clinical data used in Europe. Teijin also looks for local Chinese contract research organizations and aims to launch the drug in China through its wholly owned subsidiary Teijin Pharma Shanghai Consulting. Teijin jointly launched Uloric in the U.S. with Tekeda Pharmaceutical North America this March and plans a European market launch this autumn under Adenulic along with French pharmaceutical company Ipsen. This May, Teijin signed grant exclusive licensing rights to Astellas to develop and market the drug in Taiwan. (Click here for more - Japanese language

You may also be interested in...

Stockwatch: Reading The Entrails Of Biotech Vaccine Development

As generalist investors continue to push higher the stock prices of biotech companies that announce the most tenuous of coronavirus developments, the track record of biotech companies developing even vaccines for which the antigen is proven to be safe and efficacious remains poor.

No Love From US: Senate Bill Deals Blow To Aspiring China Biotechs

In a bipartisan move, the US Senate is moving to impose new rules on companies - including those from China - seeking US initial public offerings, adding further uncertainty over such plans and further stoking trade tensions.

Latecomer Alunbrig Faces Entrenched Rivals After US 1L Approval

First-line lung cancer approval will expand potential market for Takeda's ALK contender but the latecomer is also facing some well-established class competition in the setting.




Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts